Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Population-Level Symptom Assessment Following Pancreaticoduodenectomy for Adenocarcinoma

Population-Level Symptom Assessment Following Pancreaticoduodenectomy for Adenocarcinoma Key PointsQuestionWhat is the symptom burden of patients with pancreatic adenocarcinoma in the first year following resection? FindingsIn this population-based cohort study of 615 patients with pancreatic adenocarcinoma, we demonstrate that clinically significant symptoms are prevalent following resection, but these symptoms improve in the first 3 months following surgery and certain patient factors are associated with an increased risk of symptom reporting. MeaningTargeted interventions should be designed to preemptively address symptom burden for at-risk patient groups. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Surgery American Medical Association

Loading next page...
 
/lp/american-medical-association/population-level-symptom-assessment-following-pancreaticoduodenectomy-mxA5TgNix7

References (74)

Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2168-6254
eISSN
2168-6262
DOI
10.1001/jamasurg.2019.3348
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionWhat is the symptom burden of patients with pancreatic adenocarcinoma in the first year following resection? FindingsIn this population-based cohort study of 615 patients with pancreatic adenocarcinoma, we demonstrate that clinically significant symptoms are prevalent following resection, but these symptoms improve in the first 3 months following surgery and certain patient factors are associated with an increased risk of symptom reporting. MeaningTargeted interventions should be designed to preemptively address symptom burden for at-risk patient groups.

Journal

JAMA SurgeryAmerican Medical Association

Published: Nov 4, 2019

There are no references for this article.